Inozyme Pharma, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Inozyme Pharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
- Inozyme Pharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$24.6M, a 47.7% decline year-over-year.
- Inozyme Pharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$96.5M, a 41.6% decline year-over-year.
- Inozyme Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$71.2M, a 6.13% decline from 2022.
- Inozyme Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$67.1M, a 18.4% decline from 2021.
- Inozyme Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$56.6M, a 0.35% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)